Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
WATERTOWN, Mass., April 06, 2016 -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 15th Annual Needham & Co. Healthcare Conference on Wednesday, April 13, 2016 at 11:20 a.m. Eastern Time at The Westin Grand Central Hotel in New York City.
A live audio webcast of the Needham presentation will be available on the company's website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 30 days.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening MDR bacterial infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase’s pipeline includes three antibiotic candidates: eravacycline, its late-stage clinical candidate, TP-271 and TP-6076. Please visit www.tphase.com for more company information.
Investor Contacts: Tetraphase Pharmaceuticals Teri Dahlman 617-600-7040 [email protected] Media Contact: Sam Brown Inc. Mike Beyer 312-961-2502 [email protected] Argot Partners Susan Kim 212-600-1902 [email protected]
